

July 16, 2019



Taronis Completes First Commercial Sterilization of Cyanobacteria

Company Successfully Remediate Hibiscus Lake in Clearwater, Florida

PHOENIX, AZ / ACCESSWIRE / July 16, 2019 / Taronis Technologies, Inc., (“Taronis Technologies” or “the Company”) (**NASDAQ: TRNX**), a leading clean technology company in the renewable resources and environmental conservation industry, today announced that it has successfully completed a commercial pilot for its water decontamination technology for the remediation of cyanobacteria. The pilot project was the treatment of a cyanobacteria blue green algae bloom at Hibiscus Lake in Clearwater, Florida. The contract was vetted and approved by the city of Clearwater, and was completed last week. The Company plans to conduct further testing and monitoring for several weeks, but the initial findings indicate that cyanobacteria levels post-treatment have been dramatically reduced, and the algae bloom was successfully remediated.

“This was a positive milestone for our emerging water technology applications,” commented Scott Mahoney, CEO of Taronis. “We gathered a great deal of critical data related to the efficacy of our solution, as well as the economic viability of a commercially scalable version of our current mobile water decontamination plasma arc demonstration unit.”

“With this successful pilot, we plan to now shift our focus to seek out a potential commercial partner with whom we would look to introduce this solution at a larger scale. We have identified several promising potential partners with a strong strategic fit with our vision for a combined solution. Our goal is to identify a joint venture or licensing arrangement as soon as practically possible for our cyanobacteria solution,” concluded Scott Mahoney.

About Taronis Technologies, Inc.

Taronis Technologies, Inc. (TRNX) owns a patented plasma arc technology that enables two primary end use applications for fuel generation and water decontamination. The Company’s fuel technology enables a wide use of hydrocarbon feedstocks to be readily converted to fossil fuel substitutes. The Company is developing a wide range of end market uses for these fuels, including replacement products for propane, compressed natural gas and liquid natural gas. The Company currently markets a proprietary metal cutting fuel that is highly competitive with acetylene. The Company distributes its proprietary metal cutting fuel through Independent Distributors in the US and through its wholly owned distributors doing business as “MagneGas Welding Supply”. The Company operates 22 locations across California, Texas, Louisiana, and Florida.

The Company’s technology can also be implemented for the decontamination of waste water, including sterilizing water, eradicating all pathogens. The technology is being tested to determine if it can completely eliminate pharmaceutical contaminants such as antibiotics, hormones and other soluble drugs suspended in contaminated water. Lastly, the technology process is capable of reducing or eliminating other contaminants, such as harmful metals, as well as nitrogen, phosphorus, and potassium levels that trigger toxic algae blooms. The technology has prospective commercial applications in the agricultural, pharmaceutical, and municipal waste markets. For more information on Taronis, please visit the Company’s website at <http://www.TaronisTech.com>.

Taronis also owns a controlling interest in Water Pilot, LLC. The WATER PILOT® System immediately reduces water consumption and provides you with live remote consumption monitoring for long term leak protection and water asset management. An integral, client based alarm and notification system that reports to any mobile device. Water Pilot may be appropriate for a wide range of businesses or properties with a water meter. For more information, please visit our website at www.gowaterpilot.com/

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements

expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at <http://www.sec.gov>.

Investor Contacts:

Michael Khorassani

IR@TaronisTech.com

SOURCE: Taronis Technologies, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/551887/Taronis-Completes-First-Commercial-Sterilization-of-Cyanobacteria>